FDA Approves Higher Dose Wegovy Injection for Enhanced Weight Loss Results

The U.S. Food and Drug Administration (FDA) has approved a new, higher dose version of the GLP-1 weight loss drug Wegovy, designed to help individuals achieve greater weight loss results. The updated formulation, called Wegovy HD, delivers a weekly injection of 7.2 milligrams, significantly higher than the original 2.4 milligrams per week.

This approval, granted on March 19, marks the fourth authorization under the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program. The FDA processed the application in just 54 days, reflecting what FDA Commissioner Martin Makary, MD, MPH described as “unprecedented efficiency on products that advance national priorities.”

Why the Higher Dose Was Developed

Novo Nordisk introduced the higher dose after clinical evidence showed that while the 2.4 mg dose of Wegovy is effective for many, “some individuals do not reach their therapeutic goals” at that level, according to a 2025 trial.

Clinical Trial Results: Up to 25% More Weight Loss

In the STEP UP phase 3b trial conducted in 2025, participants using the 7.2 mg dose of Wegovy achieved an average weight loss of 18.7%. Notably, one in three participants experienced at least a 25% reduction in body weight. The FDA confirmed that the higher dose maintains a safety profile consistent with the known side effects of semaglutide.

Expert Perspective on the Higher Dose

“I’m cautiously optimistic. This has already been approved in the E.U. and the U.K. Overall, the safety data showed that serious adverse events were actually a little bit lower for the 7.2 mg group, but as always, we will have to see how this plays out in real clinical practice.”

Potential Side Effects of Higher Dose Wegovy

While the higher dose may improve weight loss outcomes, it also carries an increased risk of side effects. The most common include:

• Gastrointestinal issues: nausea, diarrhea, constipation, vomiting, and abdominal pain
• Altered skin sensations: increased reports of sensitivity, pain, or burning at higher doses

These side effects typically resolve on their own or with a dose reduction. As Dr. Garcia-Webb noted, “Many times patients will have a flare-up of side effects when they increase a dose that subsequently improves over the following weeks to months.”

Rare but Serious Risk: Eye Stroke

Recent research has raised concerns about a potential link between higher doses of Wegovy and an increased risk of ischemic optic neuropathy (ION), commonly referred to as an “eye stroke.” ION can lead to sudden vision loss or blindness. Studies suggest this risk may be higher in males, potentially due to the elevated dosage.